Business, energy, technology, markets and global industry news from Business News Today

GLP-1 drugs

PharmaDeviceNews GLP-1 drugs
Representative image: Kalohexis’ 710GO obesity drug research highlights how dual MC3R/MC4R activation could reshape oral weight loss therapy beyond GLP-1 medicines.
Pharma & Biotech

Kalohexis 710GO data highlight a differentiated obesity mechanism as Phase 1 moves ahead

Read how Kalohexis’ 710GO could challenge GLP-1 obesity drugs with dual MC3R/MC4R activation, lean-mass sparing and durability.

Read More
Zepbound KwikPen arrives on Ro as Eli Lilly tightens control over obesity drug distribution
Medical Devices & Diagnostics

Why the Ro and Eli Lilly KwikPen move matters for obesity drug access, adherence, and pricing

Ro launches Eli Lilly’s Zepbound KwikPen nationwide. Read what this means for GLP-1 access, pricing, adherence, and obesity care models.

Read More
Pharma & Biotech

How DarioHealth aims to strengthen oral GLP-1 effectiveness through precision behavioral health tools

DarioHealth targets oral GLP-1 therapy support with behavioral digital tools. Discover how digital health platforms could reshape obesity and diabetes treatment.

Read More